Supreme Court denies patent to Novartis cancer drug

The Supreme Court has denied a patent to Swiss giant Novartis AG's cancer treatment Glivec. The ruling was being closely watched by global drugmakers who have been battered by recent intellectual property decisions in India. Novartis has been fighting since 2006 to win a patent for Glivec, which many oncologists view as a major advance in treating chronic myeloid leukaemia, which kills 80-90 percent of sufferers, and some gas...